Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01314001 · ClinicalTrials.gov registry record · Phase 3
Pharmacogenetics of Nicotine Addiction Treatment
A Phase 3 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,246
- Enrollment target
NCT01314001: Completed Phase 3 study, sponsored by University of Pennsylvania.
NCT01314001 is a Phase 3 study that has completed, run by University of Pennsylvania. The registered enrollment target is 1,246 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01314001, a Phase 3 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,246 participants
- Enrollment target
Study Summary
The purpose of this research program is to understand how a biomarker called the "nicotine metabolite ratio" (also referred to as NMR) may influence a smoker's ability to quit smoking.
Interventions
- DRUG Placebo
- DRUG Varenicline
- DRUG Transdermal Nicotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,246 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01314001
The ClinicalTrials.gov registry entry for NCT01314001 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01314001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01314001 about?
NCT01314001 is a clinical study titled "Pharmacogenetics of Nicotine Addiction Treatment". The purpose of this research program is to understand how a biomarker called the "nicotine metabolite ratio" (also referred to as NMR) may influence a smoker's ability to quit smoking.
What is the current status of trial NCT01314001?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,246 participants. The study started on 2010-12. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01314001?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), Transdermal Nicotine (DRUG).
Who is sponsoring clinical trial NCT01314001?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.